CN103874504A - 疫苗 - Google Patents
疫苗 Download PDFInfo
- Publication number
- CN103874504A CN103874504A CN201280044571.4A CN201280044571A CN103874504A CN 103874504 A CN103874504 A CN 103874504A CN 201280044571 A CN201280044571 A CN 201280044571A CN 103874504 A CN103874504 A CN 103874504A
- Authority
- CN
- China
- Prior art keywords
- seq
- vaccine
- pcsk9
- fragments
- sipwnlerit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 59
- 239000012634 fragment Substances 0.000 claims abstract description 45
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 201000001320 Atherosclerosis Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 8
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 108060003552 hemocyanin Proteins 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 101710172072 Kexin Proteins 0.000 claims description 3
- 108090000787 Subtilisin Proteins 0.000 claims description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 239000001573 invertase Substances 0.000 claims description 3
- 235000011073 invertase Nutrition 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 108010044159 Proprotein Convertases Proteins 0.000 claims 1
- 102000006437 Proprotein Convertases Human genes 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract description 60
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 3
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 58
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 108010028554 LDL Cholesterol Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 102000000853 LDL receptors Human genes 0.000 description 8
- 108010001831 LDL receptors Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 200000000007 Arterial disease Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 3
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 3
- 101710135785 Subtilisin-like protease Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 2
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- MFGOTAHWOBKNNU-XMHGGMMESA-N Isodigeranyl Chemical group CC(C)=CCC\C(C)=C\CC(C)(C=C)CCC=C(C)C MFGOTAHWOBKNNU-XMHGGMMESA-N 0.000 description 2
- MFGOTAHWOBKNNU-FQEVSTJZSA-N Isodigeranyl Natural products CC(=CCCC(=CC[C@](C)(CCC=C(C)C)C=C)C)C MFGOTAHWOBKNNU-FQEVSTJZSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004777 loss-of-function mutation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710100603 Beta-fructofuranosidase, insoluble isoenzyme 1 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- -1 GMBS Chemical class 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101710195786 Invertase 1 Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 108010022249 Proprotein Convertase 9 Proteins 0.000 description 1
- 102000012343 Proprotein Convertase 9 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000005844 autocatalytic reaction Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000053786 human PCSK9 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及疫苗，其包含蛋白原转化酶枯草杆菌蛋白酶/kexin型9(PCSK9)的至少两个片段，其中所述至少两个片段包含PCSK9(SEQ ID No.9)的氨基酸残基150至170和/或205至225的至少8个连续氨基酸残基。
Description
本发明与针对PCSK9的新颖组合免疫原性肽疫苗的开发有关，所述组合免疫原性肽疫苗源自与免疫原性载体联系的两种不同PCSK9表位的组合。所述疫苗建立用于预防和/或治疗由高脂血(hyperlipidemia)，高胆固醇血(hypercholesterolemia)和动脉粥样硬化(atherosclerosis)引起的健康病症。
高脂血、高胆固醇血、高血压和动脉粥样硬化是视为全世界致死率的主要因素的心血管病症。与诸如肥胖、糖尿病、吸烟和缺乏物理活动等因素一起，形成心血管变化的主要因素是遗传病症，诸如常染色体显性高胆固醇血(ADH)。认为ADH是形成心血管病症的一项重要因素，并且表现为受损的胆固醇代谢和升高的低密度脂蛋白胆固醇水平，其随后导致形成早发冠状动脉疾病(CAD)。
已知三种主要的遗传变化可以引起ADH的形成。经典的ADH形式由低密度脂蛋白受体(下文称作LDLR)中的突变引起。另外，载脂蛋白B-100(apoB-100)中及更具体地在其配体结合域中的突变破坏ApoB-100对LDLR的结合，这随后导致受损的胆固醇代谢。最终，通过遗传变化可以牵涉ADH形成的第三种且新近发现的要素是蛋白原转化酶枯草杆菌蛋白酶/kexin型9(下文称作PCSK9)。
PCSK9，又称为神经凋亡调节转化酶1(NARC-1)，是一种鉴定为分泌性枯草杆菌酶(subtilase)家族的第9个成员的蛋白酶K样枯草杆菌酶。PCSK9蛋白以约72kDa蛋白原(proprotein)合成，该蛋白原经历前域(prodomain)和催化域之间的自身催化切割，因此导致成熟蛋白质形式的生成。前域(约14kDa)与成熟蛋白质63kDa保持结合，并且在此形式中，成熟的蛋白质向分泌途径行进。
PCSK9在脂质稳态(homeostasis)中的作用已经公知。PCSK9的表达不仅以与牵涉脂质稳态的其它SREBP响应性基因相似的方式受到固醇调节元件结合蛋白(下文称作SREBP)调节。而且，PCSK9还牵涉通过促进LDLR内在化和降解实现的低密度脂蛋白胆固醇(下文称作LDLc)清除。
体外和体内研究突出显示PCSK9在从血液摄取低密度脂蛋白胆固醇中的本质作用。在一方面，PCSK9腺病毒过表达显著提高循环LDLc的水平，而另一方面，与野生型动物相比，PCSK9-/-小鼠显示LDLR水平的2.8倍升高和LDLc降低。
基因位于人染色体1p33-p34.3，并且在组织，诸如肝、肾、小脑和小肠中表达。许多研究确认“功能获得突变(gain of function mutation)”引起LDLR水平降低及随之发生的高胆固醇血和对动脉粥样硬化的素因。“功能失去突变(Loss of function mutation)”提高LDLR的水平，随之发生低密度脂蛋白胆固醇(LDLc)的减少。
总之，PCSK9在转录后调节LDLR水平，因此是治疗动脉粥样硬化的一种有吸引力的靶物。
同时，已经建立了许多不同策略和办法来抑制PCSK9的功能。
在猴(猕猴(Macaca fascicularis))中应用针对PCSK9的siRNA导致总体胆固醇的显著减少。在小鼠和非人灵长类中用针对PCSK9的单克隆和多克隆抗体的其它调查继续上调LDLR，伴随总体胆固醇和LDLc水平的降低。
通过单克隆或多克隆抗体疗法降低PCSK9水平或小分子抑制剂和敲除技术后PCSK9的失活在不同动物模型中没有显示任何副作用。因此，总而言之，PCSK9是用于治疗动脉粥样硬化的一种非常有吸引力的靶物。
WO2011/027257涉及源自PCSK9的免疫原性片段，其可以在用于治疗、预防和减轻PCSK9介导的病症的疫苗中使用。
在WO2009/100297中，公开了人PCSK9的拮抗剂。
WO2010/057242涉及包含源自人PCSK9的片段的肽的疫苗。
本发明的目的是提供针对PCSK9的基于肽的疫苗，其能够抑制PCSK9，并且消除/降低PCSK9和LDLR的相互作用。这导致肝的肝细胞中升高的LDLR水平及随后总体胆固醇和LDLc的减少。
此目的通过疫苗实现，所述疫苗包含蛋白原转化酶枯草杆菌蛋白酶/kexin型9(PCSK9)的多种(超过一种，至少两种)片段，其中所述至少两个片段的第一片段包含PCSK9(SEQ ID No.9)的氨基酸残基150至170的至少8个连续氨基酸残基，且所述至少两个片段的第二片段包含氨基酸残基205至225的至少8个连续氨基酸残基。
令人惊讶地，证明了与仅包含一种PCSK9片段的疫苗相比，包含如上文定义的至少两种不同PCSK9肽性片段的疫苗能够有效得多地增加LDL受体量。例如，施用本发明的疫苗在肝的肝细胞中在体内导致低密度脂蛋白受体水平升高。作为其结果，施用疫苗后血浆中的LDLc和总体胆固醇的均值数值显著降低。因此，与单一肽的施用相比，施用疫苗本发明的疫苗容许以高得多的效率和准确度治疗或预防由高脂血、高胆固醇血和/或动脉粥样硬化引起的疾病。在本发明的一个优选的实施方案中，本发明疫苗的所有PCSK9片段源自由SEQ ID No.9的氨基酸残基150至170和205至225组成的PCSK9片段。
用于本发明疫苗的肽性片段包含PCSK9(SEQ ID No.9)的氨基酸残基150至170，优选氨基酸残基153至165，和205至225，优选氨基酸残基209至222的至少8个，优选至少9个，更优选至少10个连续氨基酸残基。
SEQ ID No.9(PCSK9氨基酸序列)：
源自PCSK9的片段包含优选8至20，更优选10至15个氨基酸残基或者由优选8至20，更优选10至15个氨基酸残基组成。依照本发明的一个特别优选的实施方案，源自PCSK9的氨基酸残基150至170的肽包含8至15，优选10至13个氨基酸残基。源自PCSK9的氨基酸残基205至225的肽包含8至16，优选10至14个氨基酸残基。
本发明的疫苗是源自PCSK9(SEQ ID No.9)的氨基酸残基150至170和205至225的至少2种，优选至少3种，更优选至少4种，甚至更优选至少5种肽的组合。此组合包含至少两种具有不同表位起源的序列。
本发明的肽可以通过本领域中公知的方法化学合成。当然，也有可能使用重组方法生成本发明的肽。肽可以在微生物，诸如细菌、酵母或真菌中，在真核细胞，诸如哺乳动物或昆虫细胞中，或者在重组病毒载体，诸如腺病毒、痘病毒(poxvirus)、疱疹病毒、Simliki森林病毒(Simliki forest virus)、杆状病毒、噬菌体、辛德比斯病毒(sindbis virus)或仙台病毒(Sendai virus)中生成。适合于生成肽的细菌包括大肠杆菌(E.coli)，枯草芽孢杆菌(B.subtilis)或任何其它能够表达此类肽的细菌。适合于表达本发明的肽的酵母细胞包括酿酒酵母(Saccharomyces cerevisiae)，粟酒裂殖酵母菌(Schizosaccharomycespombe)，假丝酵母属(Candida)，巴斯德毕赤酵母(Pichia pastoris)或任何其它能够表达肽的酵母。相应的手段和方法是本领域中公知的。用于分离和纯化重组生成的肽的方法也是本领域中公知的，并且包括例如凝胶过滤，亲和层析，离子交换层析，等等。
为了便于分离本发明的肽，可以生成融合多肽，其中肽与异源多肽在翻译上融合(共价连接)，所述异源多肽实现亲和层析分离。典型的异源多肽是His标签(例如His6；6个组氨酸残基)，GST标签(谷胱甘肽-S-转移酶)，等等。融合多肽不仅便于肽的纯化，而且还可以阻止纯化步骤过程中的肽降解。若期望在纯化后出去异源多肽，则融合多肽可以包含肽和异源多肽之间的接合处的切割位点。切割位点可以由用对该位点的氨基酸序列特异性的酶(例如蛋白酶)切割的氨基酸序列组成。
依照本发明，至少一种片段源自PCSK9(SEQ ID No.9)的氨基酸残基150至170，且至少一种片段源自氨基酸残基205至225。
本发明的疫苗包含PCSK9蛋白的不同部分的PCSK9片段。因此，特别优选的是，至少一种片段源自一种特定的PCSK9片段，而至少一种片段源自另一种特定的PCSK9片段。
依照本发明的另一个优选的实施方案，PCSK9的至少两种片段选自下组：具有氨基酸序列SIPWNLERITPPR(SEQ ID No.2)，PEEDGTRFHRQASK(SEQ ID No.3)，PEEDGTRFHRQA(SEQ ID No.4)，EEDGTRFHRQASK(SEQ ID No.5)，EEDGTRFHRQAS(SEQ ID No.6)，SIPWNLERITP(SEQ IDNo.7)和SIPWNLERIT(SEQ ID No.8)的肽。
PCSK9的至少两种片段也可以由选自下组的氨基酸序列组成或者包含选自下组的氨基酸序列：FAQSIPWNLERITPPRYRAD(SEQ ID No.10)，FAQSIPWNLERITPPRYRA(SEQ ID No.11)，FAQSIPWNLERITPPRYR(SEQID No.12)，FAQSIPWNLERITPPRY(SEQ ID No.13)，FAQSIPWNLERITPPR(SEQ ID No.14)，FAQSIPWNLERITPP(SEQ ID No.15)，AQSIPWNLERITPPRYRAD(SEQ ID No.16)，QSIPWNLERITPPRYRAD(SEQ ID No.17)，SIPWNLERITPPRYRAD(SEQ ID No.18)，AQSIPWNLERITPPRYRA(SEQ ID No.19)，QSIPWNLERITPPRYRA(SEQID No.20)，SIPWNLERITPPRYRA(SEQ ID No.21)，AQSIPWNLERITPPRYR(SEQ ID No.22)，QSIPWNLERITPPRYR(SEQ ID No.23)，SIPWNLERITPPRYR(SEQ ID No.24)，QSIPWNLERITPPRY(SEQ ID No.25)，SIPWNLERITPPRY(SEQ ID No.26)，AQSIPWNLERITPPR(SEQ ID No.27)，QSIPWNLERITPPR(SEQ ID No.28)，SIPWNLERITPP(SEQ ID No.29)，ENVPEEDGTRFHRQASKCDS(SEQ ID No.30)，ENVPEEDGTRFHRQASKCD(SEQ ID No.31)，ENVPEEDGTRFHRQASKC(SEQ ID No.32)，ENVPEEDGTRFHRQASK(SEQ ID No.33)，NVPEEDGTRFHRQASKCDS(SEQ ID No.34)，VPEEDGTRFHRQASKCDS(SEQ ID No.35)，PEEDGTRFHRQASKCDS(SEQ ID No.36)，NVPEEDGTRFHRQASKCD(SEQ ID No.37)，VPEEDGTRFHRQASKCD(SEQ ID No.38)，PEEDGTRFHRQASKCD(SEQ ID No.39)，NVPEEDGTRFHRQASKC(SEQ ID No.40)，VPEEDGTRFHRQASKC(SEQID No.41)，PEEDGTRFHRQASKC(SEQ ID No.42)，NVPEEDGTRFHRQASK(SEQ ID No.43)，VPEEDGTRFHRQASK(SEQ IDNo.44)，PEEDGTRFHRQAS(SEQ ID No.45)。
优选地，PCSK9的至少一种片段具有选自下组的氨基酸序列：SIPWNLERITPPR(SEQ ID No.2)，SIPWNLERITP(SEQ ID No.7)和SIPWNLERIT(SEQ ID No.8)，且PCSK9的至少一种片段具有选自下组的氨基酸序列：PEEDGTRFHRQASK(SEQ ID No.3)，PEEDGTRFHRQA(SEQ IDNo.4)，EEDGTRFHRQASK(SEQ ID No.5)和EEDGTRFHRQAS(SEQ ID No.6)。
依照本发明的一个优选的实施方案，本发明的疫苗包含SIPWNLERITPPR(SEQ ID No.2)和PEEDGTRFHRQASK(SEQ ID No.3)，SIPWNLERITPPR(SEQ ID No.2)和PEEDGTRFHRQA(SEQ ID No.4)，SIPWNLERITPPR(SEQ ID No.2)和EEDGTRFHRQASK(SEQ ID No.5)，SIPWNLERITPPR(SEQ ID No.2)和EEDGTRFHRQAS(SEQ ID No.6)，PEEDGTRFHRQASK(SEQ ID No.3)和SIPWNLERITP(SEQ ID No.7)，PEEDGTRFHRQASK(SEQ ID No.3)和SIPWNLERIT(SEQ ID No.8)，PEEDGTRFHRQA(SEQ ID No.4)和SIPWNLERITP(SEQ ID No.7)，PEEDGTRFHRQA(SEQ ID No.4)和SIPWNLERIT(SEQ ID No.8)，EEDGTRFHRQASK(SEQ ID No.5)和SIPWNLERITP(SEQ ID No.7)，EEDGTRFHRQASK(SEQ ID No.5)和SIPWNLERIT(SEQ ID No.8)，EEDGTRFHRQAS(SEQ ID No.6)和SIPWNLERITP(SEQ ID No.7)或EEDGTRFHRQAS(SEQ ID No.6)和SIPWNLERIT(SEQ ID No.8)，其中包含PEEDGTRFHRQA(SEQ ID No.4)和SIPWNLERITP(SEQ ID No.7)，EEDGTRFHRQASK(SEQ ID No.5)和SIPWNLERITP(SEQ ID No.7)，EEDGTRFHRQASK(SEQ ID No.5)和SIPWNLERIT(SEQ ID No.8)或EEDGTRFHRQAS(SEQ ID No.6)和SIPWNLERIT(SEQ ID No.8)的疫苗是特别优选的。
优选地，PCSK9的至少两种片段包含C和/或N端末端(与其结合)的半胱氨酸残基。
例如，肽的N和/或C端的半胱氨酸残基的提供可以促进其与载体的缀合，和/或可以增强肽的免疫原性。
依照本发明的一个优选的实施方案，PCSK9的至少两种片段(即至少两种源自PCSK9的肽)单独或组合与药学可接受载体，优选KLH(匙孔虫戚血蓝蛋白)偶联。
依照本发明的一个优选的实施方案，PCSK9的至少两种片段与药学可接受载体，优选KLH(匙孔虫戚血蓝蛋白)、破伤风类毒素、清蛋白结合蛋白、乙肝核心抗原、牛血清清蛋白、树枝状聚合物(dendrimer，MAP)、肽接头(或侧翼区)及Singh等,Nat.Biotech.17(1999),1075-1081(特别是所述文件的表1中的那些辅助物质)和O’Hagan等,Nature Reviews,Drug Discovery2(9)(2003),727-735(特别是其中描述的内源免疫加强化合物和投递***)中描述的辅助物质，或其混合物偶联。此上下文中的缀合化学(例如经由异双功能性化合物诸如GMBS，当然还有如记载于“Bioconjugate Techniques”,Greg T.Hermanson中的其它化合物)可以选自本领域技术人员已知的反应。此外，疫苗组合物可以与佐剂，优选低溶解性铝成分，特别是氢氧化铝一起配制。当然，也可以使用如MF59磷酸铝，磷酸钙，细胞因子(例如IL-2，IL-12，GM-CSF)，皂苷(例如QS21)，MDP衍生物，CpG寡核苷酸，LPS，MPL，聚磷腈(polyphosphazenes)，乳剂(例如弗氏(Freund’s)，SAF)，脂质体，脂肽，病毒颗粒(virosome)，Iscoms，cochleates，PLG微粒，泊洛沙姆(poloxamer)颗粒，病毒样颗粒，热不稳定肠毒素(LT)，霍乱毒素(CT)，突变体毒素(例如LTK63和LTR72)，微粒和/或聚合脂质体等佐剂。
优选地，本发明的肽经由接头与载体或佐剂结合，所述接头选自下组：NHS-聚(环氧乙烷)(PEO)(例如NHS-PEO4-马来酰亚胺)。
包含本发明的肽和药学可接受载体的疫苗可以通过任何合适的应用模式，例如皮内(i.d.)，腹膜内(i.p.)，肌肉内(i.m.)，鼻内，口服，皮下(s.c.)等及在任何合适的投递装置(O’Hagan等,Nature Reviews,Drug Discovery2(9),(2003),727-735)中施用。优选地，本发明的化合物配制用于皮内，皮下或肌肉内施用。用于获得相应的配制剂的手段和方法是本领域技术人员已知的(参见例如“Handbook of Pharmaceutical Manufacturing Formulations”,SarfarazNiazi,CRC Press Inc,2004)。
如此，依照本发明的疫苗包含至少两种肽，其优选配制用于皮内，皮下或肌肉内使用。
优选地，本发明的疫苗中的至少两种肽/片段与佐剂，优选氢氧化铝一起配制。
依照本发明的一个优选的实施方案，疫苗用于治疗和/或预防由高脂血，高胆固醇血和/或动脉粥样硬化引起的病症，优选心血管疾病，中风或外周血管疾病。
如概述的，上文提及的肽及其组合能够诱导抗体的形成，所述抗体能够特异性结合PCSK9。抗体与PCSK9的相互作用导致体内肝的肝细胞中低密度脂蛋白受体的增加及随后血浆总体胆固醇水平的降低。
优选地，与动脉粥样硬化有关的疾病选自下组：外周动脉阻塞性疾病(peripheral arterial occlusive disease)，冠状动脉疾病(coronary heart disease)，中风性脑发作(apoplectic cerebral insultus)和中风。
术语“与高脂血，高胆固醇血和/或动脉粥样硬化有关的疾病”和“由高脂血，高胆固醇血和/或动脉粥样硬化引起的病症”指作为高脂血、高胆固醇血和动脉粥样硬化后果的疾病。这些疾病包括外周动脉阻塞性疾病，冠状动脉疾病，和中风性脑发作等(参见例如Steinberg,D.J Lipid Res46(2005):179-190和Steinberg,D.J Lipid Res47(2006):1339-1351)。
依照本发明的一个优选的实施方案，对个体以每次免疫0.1ng至10mg，优选0.5至500μg，更优选1至100μg的量施用PCSK9的至少两种片段。在一个优选的实施方案中，这些量指疫苗中存在的所有PCSK9片段。在另一个优选的实施方案中，这些量指疫苗中存在的每种单一片段。当然，有可能提供如下的疫苗，其中PCSK9的特定片段以不同或相等量存在。然而，或者，本发明的肽可以以0.1ng至10mg，优选10ng至1mg，特别是100ng至300μg/kg体重的量对个体施用。
可以与载体材料组合以生成单剂形式的肽量会随治疗的宿主和特定的施用模式而变化。疫苗的剂量可以随诸如疾病状态，年龄，性别和个体体重，及抗体在个体中引发期望的应答的能力等因素而变化。可以调节剂量方案以提供最佳的治疗应答。例如，每日可以施用几个分开的剂量或者可以按比例减少剂量，如由治疗情况的紧急情况指示的。根据情况，也可以改变疫苗剂量以提供最佳的预防剂量应答。例如，总是根据针对PCSK9的抗体的水平，可以以几天，1或2周或甚至几个月或几年的时间间隔对个体施用本发明的肽和疫苗。
在本发明的一个优选的实施方案中，将肽/疫苗应用2-10，优选2-7，甚至更优选多至5且最优选多至4次。此免疫数目可以导致基础免疫。在一个特别优选的实施方案中，后续疫苗接种间的时间间隔选择为介于2周和5年之间，优选介于1个月和多至3年之间，更优选介于2个月和1.5年之间。例示的疫苗接种日程表可以包含6至8周和多至6个月的时段里的3至4次初始疫苗接种。此后，可以每2至10年重复疫苗接种。本发明的肽/疫苗的重复施用可以使治疗性疫苗接种的最终效果最大化。
本发明的疫苗还可以包含源自也牵涉人体内的LDL和/或HDL水平调节的其它蛋白质的抗原。例如，本发明的PCSK9片段可以与源自人CETP蛋白的表位组合。
通常，疫苗含有0.5至500μg，优选1至100μg并且备选0.1ng至10mg，优选10ng至1mg，特别是100ng至100μg，或备选例如100fmol至10μmol，优选10pmol至1μmol，特别是100pmol至100nmol量的本发明的肽。通常，疫苗还可以含有辅助物质，例如缓冲剂，稳定剂，等等。
依照本发明的一个优选的实施方案涉及使用两种或更多种肽。依照用于制造疫苗的本发明，所述疫苗用于预防和/或治疗动脉粥样硬化和与动脉粥样硬化有关的疾病，其中所述与动脉粥样硬化有关的疾病优选选自下组：外周动脉阻塞性疾病，冠状动脉疾病，中风性脑发作和中风。
本发明的又一个方面涉及用于治疗患有或有风险患有动脉粥样硬化和与动脉粥样硬化有关的疾病的个体的方法，在该方法的过程中，对所述个体施用依照本发明的肽或疫苗。
接着本发明的疫苗，要治疗的个体还可以接受已知影响人和哺乳动物中的LDL和/或HDL水平的其它活性成分，诸如他汀类(statins)，贝特类(fibrates)，烟酸，胆固醇摄取抑制剂(例如依泽替米贝(ezetimibe))，ApoA1Milano，脱脂化的(delipidated)HDL，植物固醇。特别优选的是，对个体施用与他汀类一起(即同时，连续，等等)的本发明的疫苗。
本发明在以下图和实施例中进一步例示，但不限于此。
图1显示了与对照动物相比，对于具有序列ID No.1(无关肽对照)，4，5，6，7和8和组合A(SEQ ID No.4和7)，B(SEQ ID No.5和7)，C(SEQ ID No.5和8)和D(SEQ ID No.6和8)的肽，肝裂解物中的低密度脂蛋白受体的量。
图2显示了对于具有序列ID No.1(无关肽对照)，4，5，6，7和8和组合A(SEQ ID No.4和7)，B(SEQ ID No.5和7)，C(SEQ ID No.5和8)和D(SEQ IDNo.6和8)的肽，总体胆固醇的血浆水平的百分比降低(n=每组5只小鼠)。
实施例：
材料和方法
疫苗：
肽经由异双功能性接头GMBS(4-马来酰亚胺丁酸N-羟基琥珀酰亚胺酯)与KLH(匙孔虫戚血蓝蛋白)缀合。
用氢氧化铝(氢氧化铝的终浓度是0.2%)悬浮15μg肽。使用磷酸盐作为缓冲剂。
表1：用于疫苗生成的序列
动物实验：
将5只Balb/c小鼠皮下免疫。小鼠可以任意使用食物和水，并在12小时光照/黑暗周期下保持。开始实验时的小鼠龄通常是8至10周。
在2周时间间隔中经由s.c.路径在总共1ml体积中给小鼠注射15μg与KLH偶联并吸附至作为佐剂的明矾的净肽(net peptide)四次。
在最终注射后约2周采集血液。
蛋白质ELISA：
为了测定疫苗的免疫原性，将96孔Nunc-Maxisorb板用重组人PCSK9蛋白包被。通过与封闭缓冲液(PBS中的1%BSA)一起温育封闭非特异性结合。将以1:2倍连续稀释的合适的血清稀释液添加至孔，并于37℃温育约1小鼠。在每个ELISA板上，包括标准血清作为内部对照。通过与生物素化的山羊抗小鼠IgG，接着是与链霉抗生物素蛋白偶联的辣根过氧化物酶一起温育检测结合的抗体。作为底物，添加ABTS，并且在微孔板阅读器中测量405nm的光密度(OD)。作为阴性对照，分析来自注射无关肽的对照组的血清。滴度定义为达到测定法中的OD最大值的50%的血清稀释。
总体胆固醇测定法
用WAKO LabAssayTM胆固醇试剂盒(Wako)测量总体胆固醇。
LDLR三明治式ELISA
为了测定鼠肝中低密度脂蛋白受体(LDLR)的水平，在最后一次疫苗接种后2周处死小鼠。将肝组织分离，并且依照标准方案完成蛋白质提取。
将96孔Nunc-Maxisorb板用经小鼠LDLR亲和纯化的山羊多克隆抗LDLR抗体(R&D Systems)包被。通过与1%BSA/PBS一起温育封闭非特异性结合。随后，将肝裂解物于室温温育3小时，以捕捉鼠LDLR。通过鸡多克隆抗LDLR抗体(Abcam)，接着与第二生物素化的山羊抗鸡IgG(Southern Biotech)一起温育及通过链霉抗生物素蛋白-HRP缀合物完成捕获的LDLR的检测。最终，使用TMB作为过氧化物酶色原底物。
通过与标准校对曲线比较完成低密度脂蛋白受体的量化，并且相对于裂解物的总蛋白质浓度标准化。
对照组(无关肽对照疫苗接种)设置为100%，并且将用抗PCSK9疫苗处理的组的水平与此对照组比较。
实施例1：针对人PCSK9的中值蛋白质滴度。(n=每组5只小鼠)。
实施例2：以mg/dL计的均值数值和总体胆固醇的降低百分比。(n=每组5只小鼠)。
实施例3：与对照组相比，体内小鼠肝中低密度脂蛋白受体的量(n=每组5只小鼠)。
Claims (10)
1.疫苗，其包含蛋白原转化酶(proprotein convertase)枯草杆菌蛋白酶/kexin型9(PCSK9)的至少两个片段，其中所述至少两个片段的第一片段包含PCSK9(SEQ ID No.9)的氨基酸残基150至170的至少8个连续氨基酸残基，且所述至少两个片段的第二片段包含PCSK9(SEQ ID No.9)的氨基酸残基205至225的至少8个连续氨基酸残基。
2.依照权利要求1的疫苗，其中所述至少两个片段选自下组：具有氨基酸序列SIPWNLERITPPR(SEQ ID No.2)，PEEDGTRFHRQASK(SEQ ID No.3)，PEEDGTRFHRQA(SEQ ID No.4)，EEDGTRFHRQASK(SEQ ID No.5)，EEDGTRFHRQAS(SEQ ID No.6)，SIPWNLERITP(SEQ ID No.7)和SIPWNLERIT(SEQ ID No.8)的肽。
3.依照权利要求1或2的疫苗，其中PCSK9的至少一个片段具有选自下组的氨基酸序列：SIPWNLERITPPR(SEQ ID No.2)，SIPWNLERITP(SEQ IDNo.7)和SIPWNLERIT(SEQ ID No.8)，且PCSK9的至少一个片段具有选自下组的氨基酸序列：PEEDGTRFHRQASK(SEQ ID No.3)，PEEDGTRFHRQA(SEQ ID No.4)，EEDGTRFHRQASK(SEQ ID No.5)和EEDGTRFHRQAS(SEQ ID No.6)。
4.依照权利要求1至3中任一项的疫苗，其中所述疫苗包含SIPWNLERITPPR(SEQ ID No.2)和PEEDGTRFHRQASK(SEQ ID No.3)，SIPWNLERITPPR(SEQ ID No.2)和PEEDGTRFHRQA(SEQ ID No.4)，SIPWNLERITPPR(SEQ ID No.2)和EEDGTRFHRQASK(SEQ ID No.5)，SIPWNLERITPPR(SEQ ID No.2)和EEDGTRFHRQAS(SEQ ID No.6)，PEEDGTRFHRQASK(SEQ ID No.3)和SIPWNLERITP(SEQ ID No.7)，PEEDGTRFHRQASK(SEQ ID No.3)和SIPWNLERIT(SEQ ID No.8)，PEEDGTRFHRQA(SEQ ID No.4)和SIPWNLERITP(SEQ ID No.7)，PEEDGTRFHRQA(SEQ ID No.4)和SIPWNLERIT(SEQ ID No.8)，EEDGTRFHRQASK(SEQ ID No.5)和SIPWNLERITP(SEQ ID No.7)，EEDGTRFHRQASK(SEQ ID No.5)和SIPWNLERIT(SEQ ID No.8)，EEDGTRFHRQAS(SEQ ID No.6)和SIPWNLERITP(SEQ ID No.7)或EEDGTRFHRQAS(SEQ ID No.6)和SIPWNLERIT(SEQ ID No.8)。
5.依照权利要求1至4中任一项的疫苗，其特征在于所述PCSK9的至少两个片段包含C和/或N端末端的半胱氨酸残基。
6.依照权利要求1至5中任一项的疫苗，其特征在于所述PCSK9的至少两个片段与药学可接受载体，优选KLH(匙孔虫戚血蓝蛋白)偶联。
7.依照权利要求1至6中任一项的疫苗，其特征在于所述PCSK9的至少两个片段配制用于皮内、皮下或肌肉内施用。
8.依照权利要求1至7中任一项的疫苗，其特征在于所述疫苗包含至少一种佐剂，优选氢氧化铝。
9.依照权利要求1至8中任一项的疫苗，其用于治疗和/或预防由高脂血(hyperlipidemia)、高胆固醇血(hypercholesterolemia)和/或动脉粥样硬化(atherosclerosis)引起的病症，优选心血管疾病(cardiovascular disease)，中风(stroke)或外周血管疾病(peripheral vascular disease)。
10.依照权利要求9的疫苗，其特征在于对个体以每剂0.1ng至10mg，优选1μg至500μg的量施用所述PCSK9的至少两个片段。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181090.9 | 2011-09-13 | ||
| EP11181090.9A EP2570135B1 (en) | 2011-09-13 | 2011-09-13 | PCSK9 Vaccine |
| PCT/EP2012/067950 WO2013037889A2 (en) | 2011-09-13 | 2012-09-13 | Vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103874504A true CN103874504A (zh) | 2014-06-18 |
| CN103874504B CN103874504B (zh) | 2017-05-31 |
Family
ID=46851983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280044571.4A Expired - Fee Related CN103874504B (zh) | 2011-09-13 | 2012-09-13 | 疫苗 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9220762B2 (zh) |
| EP (2) | EP2570135B1 (zh) |
| JP (1) | JP6054400B2 (zh) |
| KR (1) | KR101983685B1 (zh) |
| CN (1) | CN103874504B (zh) |
| AU (1) | AU2012307348B8 (zh) |
| BR (1) | BR112014005756A2 (zh) |
| CA (1) | CA2848487A1 (zh) |
| CY (2) | CY1117335T1 (zh) |
| DK (2) | DK2570135T3 (zh) |
| ES (2) | ES2565757T3 (zh) |
| HR (2) | HRP20160392T1 (zh) |
| HU (2) | HUE028583T2 (zh) |
| IL (1) | IL231043A (zh) |
| LT (1) | LT2755678T (zh) |
| MX (1) | MX346883B (zh) |
| PL (2) | PL2570135T3 (zh) |
| PT (1) | PT2755678T (zh) |
| RS (1) | RS54639B1 (zh) |
| RU (2) | RU2640258C2 (zh) |
| SG (1) | SG11201400086QA (zh) |
| SI (2) | SI2570135T1 (zh) |
| SM (1) | SMT201600082B (zh) |
| WO (1) | WO2013037889A2 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
| CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| MX2016010838A (es) * | 2014-02-28 | 2016-11-17 | Affiris Ag | Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). |
| CN105085684B (zh) * | 2014-05-14 | 2020-04-17 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
| MX2019012083A (es) | 2017-04-13 | 2019-11-21 | Cadila Healthcare Ltd | Nueva vacuna de peptidos contra la pcsk9. |
| JP2023511619A (ja) * | 2020-01-28 | 2023-03-20 | ユナイテッド・バイオメディカル・インコーポレーテッド | Ｐｃｓｋ９媒介性障害を予防及び治療するための、ｐｃｓｋ９を標的とするペプチド免疫原及びその製剤 |
| KR20210158693A (ko) * | 2020-06-24 | 2021-12-31 | 바이오스트림테크놀러지스(주) | 항 ｐｃｓｋ９ 항체 및 이의 용도 |
| JPWO2022244845A1 (zh) * | 2021-05-19 | 2022-11-24 | ||
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
| WO2011027257A2 (en) * | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101036126B1 (ko) * | 2006-05-11 | 2011-05-23 | 알닐람 파마슈티칼스 인코포레이티드 | Ｐｃｓｋ9 유전자의 발현을 억제하기 위한 조성물 및 방법 |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AT507604A1 (de) * | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
-
2011
- 2011-09-13 RS RS20160183A patent/RS54639B1/en unknown
- 2011-09-13 SI SI201130773A patent/SI2570135T1/sl unknown
- 2011-09-13 ES ES11181090.9T patent/ES2565757T3/es active Active
- 2011-09-13 DK DK11181090.9T patent/DK2570135T3/en active
- 2011-09-13 EP EP11181090.9A patent/EP2570135B1/en active Active
- 2011-09-13 HU HUE11181090A patent/HUE028583T2/en unknown
- 2011-09-13 PL PL11181090T patent/PL2570135T3/pl unknown
-
2012
- 2012-09-13 HU HUE12759427A patent/HUE031860T2/en unknown
- 2012-09-13 WO PCT/EP2012/067950 patent/WO2013037889A2/en active Application Filing
- 2012-09-13 RU RU2014114506A patent/RU2640258C2/ru not_active IP Right Cessation
- 2012-09-13 PT PT127594273T patent/PT2755678T/pt unknown
- 2012-09-13 PL PL12759427T patent/PL2755678T3/pl unknown
- 2012-09-13 DK DK12759427.3T patent/DK2755678T3/en active
- 2012-09-13 JP JP2014530217A patent/JP6054400B2/ja not_active Expired - Fee Related
- 2012-09-13 KR KR1020147009735A patent/KR101983685B1/ko active IP Right Grant
- 2012-09-13 AU AU2012307348A patent/AU2012307348B8/en not_active Ceased
- 2012-09-13 US US14/344,879 patent/US9220762B2/en not_active Expired - Fee Related
- 2012-09-13 BR BR112014005756A patent/BR112014005756A2/pt not_active Application Discontinuation
- 2012-09-13 ES ES12759427.3T patent/ES2618796T3/es active Active
- 2012-09-13 SG SG11201400086QA patent/SG11201400086QA/en unknown
- 2012-09-13 MX MX2014002879A patent/MX346883B/es active IP Right Grant
- 2012-09-13 LT LTEP12759427.3T patent/LT2755678T/lt unknown
- 2012-09-13 SI SI201230903A patent/SI2755678T1/sl unknown
- 2012-09-13 CA CA2848487A patent/CA2848487A1/en not_active Abandoned
- 2012-09-13 CN CN201280044571.4A patent/CN103874504B/zh not_active Expired - Fee Related
- 2012-09-13 EP EP12759427.3A patent/EP2755678B1/en active Active
- 2012-09-13 RU RU2017139094A patent/RU2017139094A/ru not_active Application Discontinuation
-
2014
- 2014-02-19 IL IL231043A patent/IL231043A/en active IP Right Grant
-
2015
- 2015-10-23 US US14/921,485 patent/US9669079B2/en not_active Expired - Fee Related
-
2016
- 2016-03-22 SM SM201600082T patent/SMT201600082B/xx unknown
- 2016-03-31 CY CY20161100266T patent/CY1117335T1/el unknown
- 2016-04-15 HR HRP20160392TT patent/HRP20160392T1/hr unknown
-
2017
- 2017-02-27 HR HRP20170328TT patent/HRP20170328T1/hr unknown
- 2017-03-16 CY CY20171100333T patent/CY1118856T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
| WO2011027257A2 (en) * | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
| CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103874504A (zh) | 疫苗 | |
| US20210138048A1 (en) | Peptide vaccines usable for hypercholesterolemia related diseases | |
| CN106459209A (zh) | Pcsk9疫苗 | |
| US20240197844A1 (en) | Peptide vaccines usable for hypercholesterolemia related diseases | |
| EP2532359A1 (en) | CETP fragments | |
| NZ621439B2 (en) | Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1195496 Country of ref document: HK |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1195496 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170531 Termination date: 20200913 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |